If you hit a hurdle in Microsoft Excel, press F1 to bring up the Help pane, usually to the right of the window.

464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts) J Immunother Cancer.

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...

Here are nine second-year players who need to step up this fall after rough rookie seasons: Caleb Williams, QB, Chicago Bears What's left to say about one of the most tumultuous starts in some ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology ...

SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

Rudin C, Mountzios G, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304. ASCO 2025. May 30 ...

REC has received approval from the Central government to raise funds through deep-discount bonds for a second time in less than a year, a government document dated May 30 showed.. REC has until ...

LBA8008Background: Tarlatamab, a bispecific T-cell engager (BiTE) immunotherapy, demonstrated promising activity in patients (pts) with previously treated SCLC in phase 1/2 trials. ... (CTx) as second ...

A Vancouver Canucks second line center target is officially off the market ahead of the opening of free agency in a little less than four weeks from today. It's going to be an interesting offseason ...